Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma

Journal of Surgical Research

Volumn 185, Issue 1, 2013, Pages 217-224

  Fisher, Kevin E ^a   Jani, Jigna C ^a   Fisher, Sarah B ^b   Foulks, Cora ^a   Hill, Charles E ^a   Weber, Collin J ^b   Cohen, Cynthia ^a   Sharma, Jyotirmay ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF; Carcinoma; EGFR; Immunohistochemistry; Molecular; Papillary; Thyroid

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER STAGING; CORRELATION ANALYSIS; DISTANT METASTASIS; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOMATIC MUTATION; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR INVASION;

BRAF; CARCINOMA; EGFR; IMMUNOHISTOCHEMISTRY; MOLECULAR; PAPILLARY; THYROID;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CARCINOMA, PAPILLARY; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84886721499     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.05.003     Document Type: Article

References (38)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277
2. L.G. Morris, and D. Myssiorek Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis Am J Surg 200 2010 454
3. J.A. Sipos, and E.L. Mazzaferri Thyroid cancer epidemiology and prognostic variables Clin Oncol (R Coll Radiol) 22 2010 395
4. N. Howlader, A.M. Noone, and M. Krapcho SEER cancer statistics review, 1975-2008 2010 National Cancer Institute Bethesda
5. M. Landriscina, G. Pannone, and A. Piscazzi Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans Thyroid 21 2011 1227
6. D.H. Lee, G.K. Lee, and S.-Y. Kong Epidermal growth factor receptor status in anaplastic thyroid carcinoma J Clin Pathol 60 2007 881
7. S. Hoffmann, A. Burchert, and A. Wunderlich Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines Endocrine 31 2007 105
8. S. Hoffmann, K. Maschuw, and I. Hassan Functional thyrotropin receptor attenuates malignant phenotype of follicular thyroid cancer cells Endocrine 30 2006 129
9. C. Rodríguez-Antona, J. Pallares, and C. Montero-Conde Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis Endocr Relat Cancer 17 2010 7
10. Z. Liu, P. Hou, and M. Ji Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers J Clin Endocrinol Metab 93 2008 3106
11. S.V. Sharma, D.W. Bell, J. Settleman, and D.A. Haber Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169
12. D.D. Elliott, S.I. Sherman, and N.L. Busaidy Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification Hum Pathol 39 2008 15
13. K. Masago, R. Asato, and S. Fujita Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma Int J Cancer 124 2009 2744
14. J.A. Knauf Does the epidermal growth factor receptor play a role in the progression of thyroid cancer? Thyroid 21 2011 1171
15. J.C. Ricarte-Filho, M. Matsuse, and C. Lau Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients Int J Cancer 130 2012 2215
16. T.S. Niault, and M. Baccarini Targets of Raf in tumorigenesis Carcinogenesis 31 2010 1165
17. L.R. Rowe, B.G. Bentz, and J.S. Bentz Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis J Clin Pathol 60 2007 1211
18. S.G. Lanzilotta, L. Grammatica, A. Paradiso, and G. Simone BRAF in papillary thyroid carcinoma Cell Oncol 29 2007 269
19. R. Elisei, D. Viola, and L. Torregrossa The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study J Clin Endocrinol Metab 97 2012 4390
20. G.M. Howell, M.N. Nikiforova, and S.E. Carty BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer Ann Surg Oncol 20 2012 47
21. Y.E. Nikiforov Molecular analysis of thyroid tumors Mod Pathol 24 suppl 2 2011 S34
22. C. Li, K.C. Lee, E.B. Schneider, and M.A. Zeiger BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis J Clin Endocrinol Metab 97 2012 4559
23. R.P. Tufano, J. Bishop, and G. Wu Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation Laryngoscope 122 2012 1634
24. S. Cheng, S. Serra, M. Mercado, S. Ezzat, and S.L. Asa A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior Clin Cancer Res 17 2011 2385
25. S.B. Fisher, K.E. Fisher, and S.H. Patel Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy Cancer 119 2013 454
26. S. Maithel, I. Coban, and P. Kneuertz Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection Ann Surg Oncol 18 2011 2699
27. E. Calvo, and J. Baselga Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors J Clin Oncol 24 2006 2158
28. F. Pinter, J. Papay, and A. Almasi Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry J Mol Diagn 10 2008 160
29. A.K. Lam, K.K. Lau, V. Gopalan, J. Luk, and C.Y. Lo Quantitative analysis of the expression of TGF-alpha and EGFR in papillary thyroid carcinoma: clinicopathological relevance Pathology 43 2011 40
30. U. Marti, C. Ruchti, and J. Kampf Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues Thyroid 11 2001 137
31. B.A. Schiff, A.B. McMurphy, and S.A. Jasser Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer Clin Cancer Res 10 2004 8594
32. S.M. Wiseman, H. Masoudi, and P. Niblock Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment Ann Surg Oncol 14 2007 719
33. M. Landriscina, A. Piscazzi, and A. Fabiano Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype Thyroid 19 2009 629
34. K. Schmid, N. Oehl, and F. Wrba EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases Clin Cancer Res 15 2009 4554
35. H. Shigematsu, L. Lin, and T. Takahashi Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339
36. A. Prahallad, C. Sun, and S. Huang Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100
37. N.A. Pennell, G.H. Daniels, and R.I. Haddad A phase II study of gefitinib in patients with advanced thyroid cancer Thyroid 18 2008 317
38. S.B. Fisher, K.E. Fisher, and S.K. Maithel Molecular targeted therapy for biliary tract malignancy: defining the target Hepatobiliary Surg Nutr 1 2012 53